Efficacy of bevacizumab therapy for unresectable malignant glioma: A retrospective analysis

Bevacizumab (BEV), an inhibitor of vascular endothelial growth factor A, has been used for primary and recurrent malignant gliomas in Japan since June, 2013. Previous randomized controlled studies demonstrated that BEV prolonged the progression-free survival, but not the overall survival (OS) of pat...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Mol Clin Oncol
Huvudupphovsmän: Yonezawa, Hajime, Hirano, Hirofumi, Uchida, Hiroyuki, Habu, Mika, Hanaya, Ryosuke, Oyoshi, Tatsuki, Sadamura, Yuko, Hanada, Tomoko, Tokimura, Hiroshi, Moinuddin, Fm, Arita, Kazunori
Materialtyp: Artigo
Språk:Inglês
Publicerad: D.A. Spandidos 2017
Ämnen:
Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5244831/
https://ncbi.nlm.nih.gov/pubmed/28123740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2016.1086
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk